Krystal Biotech, Inc.
KRYS
$143.96
-$2.34-1.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 116.09% | 247.53% | 473.02% | 2,722.79% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 116.09% | 247.53% | 473.02% | 2,722.79% | -- |
| Cost of Revenue | 106.79% | 311.21% | 548.38% | 7,964.13% | -- |
| Gross Profit | 116.78% | 243.64% | 468.12% | 2,582.53% | -- |
| SG&A Expenses | 25.20% | 19.84% | 15.53% | 9.35% | 8.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.87% | 32.35% | 26.63% | 22.60% | 15.10% |
| Operating Income | 3,669.46% | 342.44% | 206.14% | 147.95% | 102.86% |
| Income Before Tax | 55.70% | 133.44% | 639.37% | 292.55% | 177.19% |
| Income Tax Expenses | 801.97% | 615.57% | 215.37% | -- | -- |
| Earnings from Continuing Operations | 38.50% | 116.86% | 715.58% | 275.67% | 175.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.50% | 116.86% | 715.58% | 275.67% | 175.45% |
| EBIT | 3,669.46% | 342.44% | 206.14% | 147.95% | 102.86% |
| EBITDA | 1,936.70% | 362.81% | 213.23% | 151.80% | 105.51% |
| EPS Basic | 35.29% | 118.34% | 1,619.49% | 233.16% | 169.46% |
| Normalized Basic EPS | 440.38% | 625.72% | 263.83% | 174.36% | 123.54% |
| EPS Diluted | 34.98% | 122.84% | 3,746.21% | 220.14% | 167.17% |
| Normalized Diluted EPS | 439.69% | 604.04% | 258.35% | 172.05% | 122.74% |
| Average Basic Shares Outstanding | 1.85% | 3.35% | 5.33% | 7.24% | 9.10% |
| Average Diluted Shares Outstanding | 2.37% | 4.96% | 7.84% | 10.01% | 12.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |